Intellia’s second CRISPR therapy reduces swelling attacks by 95% in hereditary angioedema

Ryan Cross

Senior Science Correspondent

An experimental CRISPR therapy has dramatically lowered levels of an inflammation-promoting protein and reduced bouts of harmful swelling by 95% in patients with an inherited …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Intellia’s second CRISPR therapy reduces swelling attacks by 95% in hereditary angioedema

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Lilly drops body mass ranges from FDA label for weight loss drug

Coherus makes final, $483M pivot away from biosimilars

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

In­tel­lia’s sec­ond CRISPR ther­a­py re­duces swelling at­tacks by 95% in hered­i­tary an­gioede­ma

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Intellia’s second CRISPR therapy reduces swelling attacks by 95% in hereditary angioedema

Lilly drops body mass ranges from FDA label for weight loss drug

Coherus makes final, $483M pivot away from biosimilars

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech